FDA 483 - Charles J. Coté, MD - April 30, 2008

This FDA Form 483 was issued to Massachusetts General Hospital in Boston, citing significant deficiencies in clinical trial conduct. The inspection revealed multiple issues related to inadequate and inaccurate case histories, improper informed consent documentation, and lack of investigator supervision during drug administration. These findings indicate serious concerns regarding data integrity and patient protection in clinical investigations.